



(12) Translation of
european patent specification

(11) NO/EP 2552906 B1

NORWAY

(19) NO
(51) Int Cl.
C07D 401/14 (2006.01)
A61K 31/496 (2006.01)
A61P 29/00 (2006.01)

Norwegian Industrial Property Office

(21) Translation Published 2016.05.02

(80) Date of The European Patent Office Publication of the Granted Patent 2016.01.06

(86) European Application Nr. 11710087.5

(86) European Filing Date 2011.03.11

(87) The European Application's Publication Date 2013.02.06

(30) Priority 2010.03.30, US, 319015 P

(84) Designated Contracting States: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(73) Proprietor Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, NJ 08543, US-USA

(72) Inventor CHATURVEDULA, Prasad V., c/o Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492, US-USA
DUBOWCHIK, Gene M., c/o Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492, US-USA
MACOR, John E., c/o Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492, US-USA

(74) Agent or Attorney Tandbergs Patentkontor AS, Postboks 1570 Vika, 0118 OSLO, Norge


(54) Title **CGRP RECEPTOR ANTAGONIST**

(56) References Cited: WO-A1-03/104236
PAONE D V ET AL: "Calcitonin gene-related peptide receptor antagonists for the treatment of migraine: A patent review", EXPERT OPINION ON THERAPEUTIC PATENTS, INFORMA HEALTHCARE, GB, vol. 19, no. 12, 1 December 2009 (2009-12-01), pages 1675-1713, XP002572832, ISSN: 1354-3776, DOI: DOI:10.1517/13543770903359822

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

- 5 **1.** Forbindelse (R)-N-(3-(7-metyl-1H-indazol-5-yl)-1-(4-(1-metyl-piperidin-4-yl)piperazin-1-yl)-1-oksopropan-2-yl)-4-(2-okso-1,2-dihydrokinolin-3-yl)piperidin-1-karboksamid, eller et farmasøytisk akseptabelt salt derav.



- 10 **2.** En farmasøytisk sammensetning omfattende en terapeutisk effektiv mengde av (R)-N-(3-(7-metyl-1H-indazol-5-yl)-1-(4-(1-metyl-piperidin-4-yl)piperazin-1-yl)-1-oksopropan-2-yl)-4-(2-okso-1,2-dihydrokinolin-3-yl)piperidin-1-karboksamid i assosiasjon med et farmasøytisk akseptabelt hjelpestoff, bærer eller fortyner.
- 15 **3.** Forbindelse ifølge krav 1, eller et farmasøytisk akseptabelt salt derav, for anvendelse i en fremgangsmåte for behandling av inflammasjon, smerte, termisk skade, kretsløpssjokk, diabetes, Reynauds syndrom, perifer arteriell insuffisiens, subaraknoid-/hjerneblødning, tumorvekst, hetetokter i forbindelse med overgangsalder.
- 20 **4.** Forbindelse ifølge krav 1, eller et farmasøytisk akseptabelt salt derav, for anvendelse i en fremgangsmåte for behandling av migrene.
- 5.** Forbindelse ifølge krav 1, eller et farmasøytisk akseptabelt salt derav, for
- 25 anvendelse i en fremgangsmåte for behandling av nevropatisk smerte.
- 6.** Forbindelse ifølge krav 1, eller et farmasøytisk akseptabelt salt derav, for anvendelse i en fremgangsmåte for behandling av en proliferativ sykdom.

7. Forbindelse eller et farmasøytisk akseptabelt salt derav, for anvendelse i henhold til krav 6, hvor den proliferative sykdommen er brystkreft eller gliom.